Several Flavobacterium species, comprising a heterogeneous group of gram-negative bacilli that are capable of causing opportunistic infections in humans, have recently been reclassified as Chryseobacterium or Myroides species. Intrinsically resistant to a number of antibiotics, these organisms have been reported to be susceptible to vancomycin and certain other drugs that are normally active against gram-positive bacteria. By using the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution procedure, 58 clinical isolates of former flavobacteria (36 Chryseobacterium meningosepticum isolates, 11 C. indologenes isolates, 3 C. gleum isolates, 4 unspeciated former members of Flavobacterium group IIb, and 4 Myroides odoratum isolates) were tested with 23 antibiotics, including conventional and investigational agents. In addition, the broth microdilution results were compared to those generated by agar dilution, E-test, and disk diffusion for vancomycin and piperacillin-tazobactam. Compared to the NCCLS microdilution results, there were 7.1 and 17.9% very major errors with piperacillin-tazobactam by agar dilution and E-test, respectively. In addition, there were from 12.1 to 48.3% minor errors with both procedures with vancomycin and piperacillin-tazobactam. The very major and minor error rates were unacceptably high with disk testing of piperacillin-tazobactam; the use of enterococcal vancomycin disk breakpoints (zone diameter of >17 mm ‫؍‬ susceptible) resulted in >20% minor errors but only one very major error. All of the isolates were susceptible to minocycline; over 90% were susceptible to sparfloxacin, levofloxacin, and clinafloxacin; and 88% were susceptible to rifampin. None was susceptible to vancomycin. When Chryseobacterium or Myroides species are isolated from serious infections, susceptibility testing by broth microdilution should be performed and therapy should be guided by those results.
Members of the genera Chryseobacterium and Myroides (formerly classified as Flavobacterium species) in the family Cytophagaceae comprise a heterogeneous group of nonmotile, oxidase-positive, nonfermentative or slowly fermentative gram-negative bacilli (26, 27) . Chryseobacterium meningosepticum is the species most commonly associated with infections in humans. It can cause neonatal meningitis, pneumonia, bacteremia, sepsis, and soft tissue and other infections primarily in immunocompromised patients and has been a well-documented cause of outbreaks in neonatal and adult intensive care units (6, 7, 11) . The other former flavobacteria have been isolated from a variety of clinical and environmental sources. The most common of these former flavobacteria are Myroides odoratum (4, 10, 12, 14) and members of Flavobacterium group IIb, including Chryseobacterium indologenes (13) and Chryseobacterium gleum (27) .
All of these species are known to be resistant to a number of antimicrobial agents. C. meningosepticum has the unusual reputation of being susceptible to vancomycin (11) and to other agents that are commonly used to treat infections caused by gram-positive bacteria, such as erythromycin (2, 11, 20, 21) and clindamycin (8, 9) .
In prior studies with these bacteria, the results of disk diffusion susceptibility tests agreed poorly with MIC determinations, particularly in the interpretation of results for vancomycin (1, 8, 28) . In their recent comprehensive review of C. meningosepticum, Bloch et al. (6) described a complete failure of vancomycin in vitro for their series of isolates; after a review of the literature, they found that only 65% of organisms demonstrated in vitro susceptibility to vancomycin. In many of their cited references, disk diffusion susceptibility testing was employed.
Other more recent reports provide conflicting data regarding the susceptibilities of chryseobacteria to drugs that are generally considered to be effective against gram-negative bacilli, including piperacillin and piperacillin-tazobactam (4, 8, 9, 13, 16, 23, 29) . In our own recent experience with a few clinical isolates, we found them to be susceptible to piperacillin-tazobactam by disk diffusion criteria.
We undertook our study in order to confirm the previously reported susceptibilities of these former flavobacteria, corroborate the results of prior studies which concluded that disk diffusion susceptibility testing is unreliable for these isolates, explore the potential activities of newer antimicrobial agents against a substantial number of isolates, and assist clinicians with decisions regarding empiric antibiotic choices for their patients with infections caused by Chryseobacterium and Myroides species.
MATERIALS AND METHODS
Isolates. Frozen, lyophilized, and stock cultures of clinical origin and fresh clinical isolates were employed for this study. The identities of all isolates were confirmed by the Vitek system, incorporating GNI cards (bioMerieux Vitek, Hazelwood, Mo.) and/or apiNFT (bioMerieux). Disk diameters and all MIC results were interpreted by using NCCLS interpretive standards, if available, for nonfastidious gram-negative bacteria. For vancomycin, erythromycin, and clindamycin, gram-positive bacteria breakpoints were employed; for vancomycin disk susceptibilities, both staphylococcal and enterococcal criteria of NCCLS were applied for interpretation.
RESULTS
We tested a total of 58 clinical isolates of Chryseobacterium and Myroides species with 23 antibiotics, including traditional agents as well as new and investigational agents. The broth microdilution MIC determinations for 36 C. meningosepticum, 18 former Flavobacterium group IIb (11 C. indologenes, 3 C. gleum, and 4 unspeciated), and 4 M. odoratum isolates are shown in Table 1 . The pattern of growth at the bottoms of piperacillin-tazobactam and cefepime wells was frequently atypical, appearing somewhat filmy or diaphanous at higher concentrations of antibiotic, possibly suggesting partial inhibition of ␤-lactamase. In some cases, the endpoints (Ͼ80% inhibition) for trimethoprim-sulfamethoxazole were difficult to read.
Minocycline, sparfloxacin, levofloxacin, clinafloxacin, and rifampin were the most active drugs tested. The 58 isolates examined demonstrated very similar susceptibility patterns, with a few exceptions; 35 of 36 C. meningosepticum isolates were susceptible to rifampin, but only 73% of isolates of other species were fully susceptible. Only one-quarter of C. meningosepticum and M. odoratum isolates were susceptible to ciprofloxacin, but 94% of the former Flavobacterium group IIB isolates were susceptible. Thirty-five C. meningosepticum isolates were resistant to imipenem, and all were resistant to meropenem and cefepime. All three isolates of C. gleum were susceptible to cefepime at low concentrations, and two of the unspeciated group IIb isolates were susceptible at somewhat higher concentrations.
We also tested all 58 isolates with vancomycin and piperacillin-tazobactam by agar dilution, E-test, and disk diffusion techniques and compared the results with those obtained by broth microdilution.
For vancomycin, over 95% of the MICs determined by agar dilution and E-test agreed within 1 log 2 dilution of the results obtained by broth microdilution (Table 2 ). There were no major or very major errors, but 15.5 and 12.1% minor errors occurred with agar dilution and E-test, respectively. With the disk diffusion method, there were 37% very major errors and 50% minor errors when the staphylococcal zone criteria (Յ9 mm, resistant; 10 to 11 mm, intermediate; Ն12 mm, susceptible) were used for interpretation. However, when we employed the enterococcal zone criteria (Յ14 mm, resistant; 15 to 16 mm, intermediate; Ն17 mm, susceptible), only one very major error and 20.7% minor errors were noted, e.g., an isolate considered resistant by MIC and intermediate by the disk test.
For piperacillin-tazobactam, only 64% of the MICs determined by agar dilution and 53% of the MICs determined by E-test were within 1 log 2 dilution of the results obtained by broth microdilution. There were from 7.1 to 31% very major errors and approximately 50% minor errors with each of these techniques compared with the results obtained by broth microdilution. One major error was also noted.
DISCUSSION
Since the original characterization of Flavobacterium species in 1959, several taxonomic modifications and methods for differentiating species within this genus have been proposed. Most recently, ribotyping and DNA hybridization techniques led to the creation of two new genera, Chryseobacterium and Myroides (26, 27) . Some formerly designated Flavobacterium species have been placed into the genera Sphingobacterium, Weeksella, and Empedobacter and unnamed Centers for Disease Control and Prevention groups. These organisms do not have the antimicrobial resistance characteristics for which chryseobacteria and M. odoratum are notable.
Clinicians from time to time are faced with the challenge of treating opportunistic infections caused by chryseobacteria and other former Flavobacterium species. Because infections with Chryseobacterium and Myroides species are being reported more frequently (4, 10, 13, 14, 17, 23, 25) , we thought it was an opportune time to look at new and older antimicrobial agents and their in vitro effectiveness against a number of clinical isolates. The literature provides some contradictory information about drugs which may be used for empirical therapy and about the in vitro susceptibilities of previously isolated strains.
In many reports, susceptibility testing was performed by disk diffusion, which has previously been shown to be inaccurate for these organisms (1, 8, 28 ). An automated dilution method of susceptibility testing (Vitek) was shown to be less accurate than was disk susceptibility testing (7, 23) . Furthermore, early studies frequently tested antibiotics which are not currently considered to be effective against gram-negative bacteria and varied interpretive (disk diffusion) and breakpoint (MIC) criteria were used for assigning isolates to susceptible and resistant categories (1, 2, 22) or those criteria were not listed (11, 20, 21) .
Our findings demonstrated poor correlation between disk diffusion and microdilution results when vancomycin was tested and very poor correlation between disk, E-test, or agar dilution results and microdilution results with piperacillin-tazobactam. The reasons for the discrepant results are unclear, but there may be discrepancies because the broth dilution technique does not require the diffusion of drugs through agar.
We also noted the unusual appearance of growth in many of the piperacillin-tazobactam wells, suggesting partial inhibition. This effect may not have been apparent in reading disk, agar diffusion, and E-test results.
The most effective drugs that we tested were minocycline, the newer fluoroquinolones, and rifampin. Twenty percent of isolates showed intermediate susceptibilities to vancomycin, but the remainder were resistant (according to the published criteria of NCCLS for gram-positive organisms). Our MIC results for vancomycin, erythromycin, clindamycin, lincomycin, quinupristin-dalfopristin, and two investigational oxazolidinone agents (linezolid and eperezolid) designed to treat infections caused by gram-positive bacteria do not support previous observations that C. meningosepticum is susceptible to antimicrobial agents that have traditionally been reserved for treating infections caused by gram-positive bacteria.
In this study, we did not attempt to correlate our in vitro results with clinical efficacy. In vitro data may not always predict clinical outcome when infections with chryseobacteria are encountered; therefore, MICs may be no more valid than are E-test or disk results in testing these bacteria. However, infections caused by C. meningosepticum are often lethal, and broth dilution testing is often considered to be the reference method of choice in the United States for antimicrobial susceptibility testing. Our data indicate that with these organisms, differences may exist between the results determined by broth-and agar-based tests. We cannot determine from our results the source of this discrepancy. Future studies may compare methodologies for those compounds with lower MICs and provide additional clinical reports of in vitro results compared with in vivo efficacy.
Some published reports have documented the successful use of vancomycin to treat patients with infections caused by C. meningosepticum (11, 23) , and at least one reference recommends vancomycin as the therapy of choice (24) . However, George et al. also described several clinical failures when vancomycin was employed (11) . Several reports (1, 2, 6, 8, 23) have documented the susceptibility of C. meningosepticum isolates to rifampin and its successful use in treating neonatal meningitis caused by this organism (18, 25) . In a few cases, ciprofloxacin has been used successfully to treat infections caused by M. odoratum and Chryseobacterium species. The use of minocycline has previously been reported for only two cases (6), even though multiple studies have documented its activities against these organisms in vitro (13, 15, 23, 29) . Although cephalosporins and other ␤-lactam antibiotics have occasionally been used to treat infections caused by chryseobacteria, their in vitro activities are poor compared with those of the most effective drugs in our study and earlier studies. Both M. odoratum and C. meningosepticum produce a chromosomally mediated noninducible metallo-␤-lactamase which is capable of hydrolyzing cephamycins, penicillins, cephalosporins, aztreonam, imipenem, and meropenem (5). Despite their low levels of virulence, these bacteria are resistant to many antimicrobial agents, which may favor nosocomial infections or infections in immunocompromised individuals due to the selection of strains by using broad-spectrum antibiotics. C. meningosepticum has previously been documented to acquire resistance during therapy with drugs to which it was originally susceptible in vitro (6, 18) . Earlier studies (3, 8, 15, 16) reported higher susceptibilities of chryseobacteria to ciprofloxacin and ofloxacin than have more recent studies (6, 7, 13, 23) , suggesting that as fluoroquinolone use has increased, so has selection pressure to develop resistance.
When significant infections with chryseobacteria or Myroides strains are encountered, susceptibility testing should be performed by a broth microdilution technique and therapy should be guided by those results.
